GPT-Rosalind

Headlines · 6

1. 2d
   OpenAI outlines proactive AI health assistant and clinician copilot plans

   OpenAI health lead Karan Singhal said the company is exploring a proactive personal health assistant spanning pre-visit, in-visit and post-visit care, including appointment, insurance, treatment-plan and billing support. OpenAI is also testing Clinician Copilot with Penda Health and working with Epic to bring ChatGPT into clinical workflows. The interview also covered life-science efforts involving GPT-Rosalind and the acquisition of Orchestra Bio.

   36氪 人工智能 · 🔥 3
2. 5d
   AI Agents Enter Automated Wet-Lab Workflows

   Frontier AI companies are extending AI beyond molecular design and screening by connecting research agents with automated wet laboratories. The report says Anthropic proposed the MHS hardware standard to give agents unified access to instruments, while Google introduced VERID, a framework for tracking laboratory states and operation histories. It also reports that Google’s agents completed three design-test-analysis cycles for an adapter-design experiment. OpenAI and Ginkgo Bioworks reportedly ran six cycles involving more than 36,000 reaction combinations and reduced cell-free protein-synthesis costs by about 40%. These demonstrations are described by the report as early closed-loop systems, with data interoperability and reliable laboratory-state modeling still key challenges.

   虎嗅 AI · 🔥 0
3. Oct 21
   GPT-Rosalind agents analyze mouse brain atlas in 32 minutes

   OpenAI, PerturbAI and Scripps Research used 1,946 GPT-Rosalind agents to analyze a whole-brain CRISPR atlas covering millions of mouse brain cells, completing the reported analysis in 32 minutes. The distributed agents linked gene disruption effects to scientific literature and generated leads involving Tsc1, Tsc2 and DCTN1. In blinded comparisons, experts preferred distributed-agent reports over single-agent reports 75% of the time, though the resulting bioRxiv preprint has not undergone peer review and the biological hypotheses still require laboratory validation.

   OpenAI · 🔥 0
4. Oct 20
   OpenAI acquires Orchestra Bio to add drug-development agents to Rosalind

   OpenAI said it has acquired Orchestra Bio, a platform that helps biopharma teams coordinate drug development, and will combine its team and technology with Rosalind, OpenAI's AI models and tools for life sciences research. Financial terms were not disclosed; Chinese outlets report Orchestra was founded in San Francisco in 2022 and had raised about $20 million from investors including a16z, 8VC and Insight Partners as of August 2025. OpenAI says Orchestra's agents are designed to track trials and flag affected timelines when something goes wrong, such as a failed production batch, and that Rosalind already counts Moderna and Novo Nordisk as customers. OpenAI frames the deal as a step toward agents that connect scientific findings with the studies, decisions and next steps needed to advance a potential medicine.

   OpenAI · 🔥 0
5. Oct 15
   OpenAI launches Rosalind Academic Plan with up to 30 free GPT-Rosalind seats

   OpenAI introduced the Rosalind Academic Plan, which gives academic labs at U.S. universities up to 30 Business Standard seats at no cost for up to 12 months, centered on GPT-Rosalind, its life-sciences model, plus the Rosalind Workbench for tool orchestration across medicinal chemistry, genomics and wet-lab assistance. Access requires trusted-access approval: OpenAI verifies the institution, the PI or lab lead and the intended use, then continues monitoring, with safety checks that account for approved research context in registered high-sensitivity cases and follow-ups when use is unclear. OpenAI says research data shared through the plan is not used to train its models by default, API access is not included, and labs at universities with an existing enterprise agreement must apply through that process.

   OpenAI · 🔥 0
6. Oct 10
   OpenAI pricing page lists unannounced gpt-rosalind-discovery life sciences model

   TestingCatalog reported that OpenAI's API pricing page now lists an unannounced model, gpt-rosalind-discovery, under a "Life sciences models" section next to the already public gpt-rosalind-research, with identical pricing of $5 per million input tokens, $0.50 per million cached input tokens and $25 per million output tokens. There is still no blog post, help article or system card for it, and MIT Technology Review China said the model documentation pages return 404 errors, leaving pricing as the only published information. Outside observers guess from the "discovery" name that it targets drug discovery, but its purpose, its relationship to the research model and any real gains remain undisclosed.

   TestingCatalog · 🔥 0

Experience and discussion from the community

Share my GPT-Rosalind experienceAsk about GPT-Rosalind